Auditorium or Zoom seminar
30 Sep 2020 9:30am to 10:30am
07 Oct 2020 9:30am to 10:30am
14 Oct 2020 9:30am to 10:30am

UQDI Webinar Seminar Series

This is a weekly series open to all occupants to attend. This will be a Zoom webinar and is password protected. To register for this seminar, please email: [email protected]

Date Presenter Seminar Title Speaker Bio Location and Time
Wednesday 30 September 2020

Associate Professor Graham Leggatt and Quentin Wright

"From parasites to cancer: a career centred on immunology "

"Evaluation of intradermally delivered immunotherapeutic antibodies in a mouse cutaneous tumour model"

Dr Leggatt completed a PhD in 1993 at QIMR investigating the serodiagnosis of hydatid disease before moving to the NIH (USA) for postdoctoral research on CD8 T cell recognition of viral peptides.   Upon returning to Australia, he has worked for many years with Prof. Ian Frazer on immunotherapy of HPV-mediated cervical cancer.  In recent years, he has been a senior lecturer in immunology at the University of Queensland and conducted research into the development and regulation of T cells residing in precancerous skin.

Quentin graduated from the National University of Ireland in 2001 with a Bachelor of Science. He moved to the United States and was a visiting scholar in Dr. Carol Warner’s lab at Northeastern University, studying the contribution of the Ped gene to embryonic development in mice. He then transitioned to Industry, first working on the IRAK4 program at Pfizer, Sirtuin inhibitors and Ghrelin antagonists at Elixir pharmaceuticals, and HDAC inhibitors at GSK.  After leaving GSK, Quentin worked with colleagues at Verastem inc to help bring, Copiktra, a dual PI3K delta/gamma inhibitor to market for patients with Chronic lymphocytic leukaemia / small lymphocytic lymphoma. Quentin Later worked at Moderna Inc, Atlas Ventures and Immunext, and graduated with a Master’s degree from Harvard University in 2017. 

9:30am-10:30am

Zoom only. Contact [email protected] for seminar link.

Wednesday 23 September 2020 Hanumanth Srikanth Cheruvu and Dr Zeng (Frank) Guo  

"Modelling approaches to predict human skin absorption of drugs and other chemicals" Presented by Hanumanth Srikanth Cheruvu

"Histopathological, biochemical and genetic characterisation of different types of primary aldosteronism, including validation of a new angiotensin assay" Presented by Dr Zeng (Frank) Guo

Hanumanth Srikanth Cheruvu is a Ph.D. student in the Therapeutics Research Centre group at the University of Queensland Diamantina Institute. He completed his Master’s degree in Pharmaceutics in 2012 from NIPER-Hyderabad (India). He has five years of experience working in Pharma, Biotech and in drug discovery CRO’s working in disciplines of drug metabolism and pharmacokinetics (DMPK), formulation technology, drug delivery, and bioanalysis. Currently, his research focus is on various modelling approaches for predicting the human skin absorption of drugs and other chemicals based on in silico and in vitro techniques.

Zeng (Frank) Guo graduated from the University of Queensland Diamantina Institute and obtained his PhD degree in July 2020. As followed with Prof Michael Stowasser and Dr Martin Wolley, his research directions are to explore the characterisation of different types of primary aldosteronism and to validate the effectiveness of a novel angiotensin assay on hypertensive patients in different clinical scenarios.

9:30am-10:30am

Auditorium and Zoom. Contact [email protected] for seminar link.

Wednesday 16 September 2020 Professor Louise Purton, St Vincent’s Institute. 'Key roles of Hoxa1 in HSCs and myelodysplatisc sydndromes.'

Professor Louise Purton received her PhD from The University of Melbourne in 1995 and undertook post-doctoral studies at the Fred Hutchinson Cancer Research Center in Seattle. She returned to Australia at the end of 2000 to the Peter MacCallum Cancer Centre. Prof Purton continued this research while she was a visiting scientist in Professor David Scadden’s laboratory at Massachusetts General Hospital in Boston, 2004-2007. Louise returned to Melbourne in 2008 to establish and head the Stem Cell Regulation Unit at St. Vincent’s Institute. She was an Associate Director there from 2010, voluntarily resigning from this position in 2019. She is continuing her research on how haematopoiesis is regulated both intrinsically and extrinsically in normal and diseased states. Louise has a passion for translational research and to date her senior author research has resulted in four clinical trials.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Monday 14 September 2020 A/Prof Jessica Mar, AIBN 'One of these cells is not like the other – how variability of gene expression highlights regulatory control.'

Associate Professor Jessica Mar's research group focuses on the development of bioinformatics methods to understand how regulatory processes go awry in human diseases. Specifically, the groups is interested in modelling how variability of gene expression contributes to regulation of the transcriptome. The group looks to modern tools in statistics, such as Bayesian methodologies and machine learning algorithms, to make sense of biology from big data.

12:00pm-1:30pm

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 9 September 2020 Dr Giorgia Mori and Rachel Rollo 'Characterisation of a novel antimicrobial lead against Mycobacterium tuberculosis'

Dr. Giorgia Mori is a Molecular Microbiologist passionate about finding solutions that help address the global health emergency posed by tuberculosis (TB). Her work focuses on the characterization of new TB drug leads, in order to overcome the major limitations associated with the currently available TB treatments. In 2019, she relocated from Italy to Australia, to take up the opportunity to drive the pre-clinical characterization of a highly promising novel TB drug lead in an internationally funded program at the University of Queensland (UQ, A/Prof. Antje Blumenthal's lab) that brings together a multi-disciplinary international team of microbiologists, immunologists and chemists.

Rachel Rollo is a PhD student in the Blumenthal lab at the Diamantina Institute, The University of Queensland. Rachel's research is characterising new antimicrobials for the treatment of Mycobacterium tuberculosis. She has general interests in the fields of microbiology and immunology, and has previously worked on host-pathogen interactions in Listeria monocytogenes and macrophages, and Pseudomonas aeruginosa and "inhibitory" antibodies.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 2 September 2020 Prof Sarah-Jane Dawson 'Blood worth bottling: Circulating tumour DNA in cancer'

Professor Sarah-Jane Dawson is a clinician-scientist. Following postdoctoral studies at the Cancer Research UK Cambridge Institute, she returned to Melbourne in 2014 to head the Molecular Biomarkers and Translational Genomics Laboratory at the Peter MacCallum Cancer Centre. She also holds a joint appointment with the Centre of Cancer Research at The University of Melbourne (since 2016) and currently holds a CSL Centenary Fellowship (2018-2022). Her current research interests are focused on the development of non-invasive blood-based biomarkers ('liquid biopsies') for clinical application, including early detection, risk stratification and disease monitoring in cancer management.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 26 August 2020 Michelle Wykes  Long Road to Licensing'

Michelle Wykes is Group Leader of the Molecular Immunology Laboratory at the QIMR Berghofer. Her group first showed Programmed cell death-1 (PD-1) and its ligands PD-L1 and PD-L2 (both expressed on dendritic cells) were primary drivers of chronic and severe malaria. Her group then published a paradigm–shifting study, which showed PD-L2 has a regulatory role in mediating immunity. They showed PD-L2 is crucial for establishing effective CD4+ Th1 immunity and designed a novel form of soluble PD-L2, which cures malaria and protects against re-infection, 150 days after the original infection. This line of research, published in Immunity, Journal of Clinical Oncology and Nature Reviews Immunology, has led to several patents, funding to develop two novel treatments for cancer and one for inflammatory diseases and a recent deal with Pharma.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 19 August 2020 Guest Speakers Dr Nicolas Jacquelot and Dr Michael Chopin 

"Deciphering Innate Lymphoid Cell Function in Melanoma Immunity" presented by Dr Nicolas Jacquelot 

"Molecular Insights into the First Line of Defence" presented by Dr Michael Chopin

Nicolas Jacquelot’s Bio: In 2017, Dr Nicolas Jacquelot joined Professor Gabrielle Belz’s group at The Walter and Eliza Hall Institute of Medical Research, aiming to decipher the role and function of the recently discovered innate lymphoid cells in cancer, particularly in melanoma. Dr Jacquelot’s research focused on the identification of predictive and prognostic immunological markers influencing patient clinical outcomes and responses to treatment as well as on the identification of resistance mechanisms to immune checkpoint blockers.

Michael Chopin’s Bio: Dr Michael Chopin’s research currently focuses on three complementary areas: 1) The definition of the molecular pathways controlling myeloid cell ontogeny, 2) The development of new methodologies to increase DC yield for therapeutic benefit, 3) The identification of novel regulator of myeloid effector functions by performing whole genome CRISPR/Cas9 screens in vivo.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 5 August Prof Riccardo Dolcetti and Dr Bijun Zeng  Is there a role for cancer vaccine in the immune checkpoint inhibitors and CAR-T era?

Prof. Riccardo Dolcetti is a clinician scientist with MD specializations in Oncology and Clinical Immunology with >20 y research experience in cancer cell biology and immunology. His main scientific background and expertise are in the areas of tumour immunology and cancer immunotherapy. The major contributions of his research over the last 5 years are: development of “off-the-shelf” idiotypic vaccines for B-cell lymphomas (PCT/IB2008/001936); development of a therapeutic antibody (PCT/EP2016/076691) and an innovative adoptive immunotherapy protocol for the treatment of EBV-driven malignancies; identification of immunological correlates of the induction of pathological complete response in breast cancer patients treated with neoadjuvant immuno-chemotherapy; co-development of a nanoemulsion-based vaccination platform delivering antigens to cross-presenting dendritic cells in vivo. 

Bijun is currently a Senior Research Officer in Professor Riccardo Dolcetti’s group where she is actively characterising TNE-based cancer vaccines exploiting different antigen formulations, with particular focus on their ability to overcome immune-resistance mechanisms. She has also developed a pipeline to functionally validate the immunogenicity of candidate (neo-)antigen epitopes as well as advanced assays to monitor polyfunctional T cell responses to tumour antigens in both mouse models and cancer patients.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 29 July A/Dr James Wells and Jenny Zeng  Developing novel treatments to combat cutaneous squamous cell carcinoma

Dr James Wells received his PhD from King’s College London and undertook postdoctoral training at Harvard Medical School. He now leads the Skin Cancer Immunotherapy Group at The University of Queensland Diamantina Institute. His main research interest lies in understanding the role of T cells in the recognition and control of squamous cell carcinoma in the skin, and how they can be exploited to control SCC lesions in patients with extensive disease. He has recently developed and patented a drug to reduce the skin cancer incidence in immune-suppressed organ transplant recipients, which he is presently developing for testing in clinical trials. 

Zhen Zeng joined the Wells Lab at The University of Queensland Diamantina Institute in 2017 for PhD program training. Her project focuses on investigating the role of CD8+ T-cells in the regression of squamous cell carcinoma.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 22 July A/Prof Rick Strum and Dr Mitchell Stark

'4-decade odyssey in scientific research: from genes to dermatology' presented by A/Prof Rick Sturm

'Mutational signatures in benign neoplasms of the skin' presented by Dr Mitchell Stark 

Rick Sturm’s Bio: A/Prof Sturm trained as a molecular biologist and has been an active research scientist for 40 years. His research focus is the biology of the melanocyte cell and pigmentation genetics in relation to human skin cancer, skin UV-sensitivity, freckling, iris colour and naevi (mole) formation.  Landmark publications from his laboratory have described the genetic association between human MC1R gene variant alleles (the gene for red hair), skin type, tanning and UV repair, and the cellular and biochemical properties of the variant forms of the MC1R receptor.  More recently he has examined the genes underlying the type and number of naevi, and the interaction of MC1R genotype and total body naevi in the risk of melanoma in the Queensland population.

Mitchell Stark’s Bio: Dr Stark is currently a University of Queensland (UQ) Amplify Research Fellow based in the Dermatology Research Centre, at The UQ Diamantina Institute. He was awarded his PhD in 2015 and has been actively working in the field of melanoma and naevi genomics and biomarker development for 20+ years. His teams primary research focus is identifying early signs of melanoma progression via ‘melanoma-specific’ microRNAs as well as genomic profiling of precursor skin lesions that may be useful for clinical management of disease. He is the author of 68 scientific publications and one patent (h-index, 34).
 

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 15 July Prof H. Peter Soyer and Brigid Betz-Stablein Australian Centre of Excellence for Melanoma Imaging and Diagnosis (ACEMID) and first results of the “Mind Your Moles” Study

Prof H. Peter Soyer has a dual academic/clinical role as the inaugural Chair and Director Dermatology Research Centre, The University of Queensland Diamantina Institute, and as Director Princess Alexandra Hospital Dermatology Department. Professor Soyer, an academic dermatologist from Austria, is a world leader in the field of dermatology with particular expertise in dermato oncology and dermatologic imaging. His research group’s main focus is skin cancer, both melanoma and keratinocyte skin cancer. He has an extensive publication record with over 500 publications (>135 publications in the last 5 years), over 700 citations a year and a Hirsch index of 52 (Researcher ID). He initiated establishment and is Co-leader of the Australian Skin and Skin Cancer (ASSC) Research Centre.

Brigid Betz-Stablein is an early career research fellow with the NHMRC Centre of Research Excellence for the study of Naevi. She has dual appointments with the Dermatology Research Centre, The University of Queensland Diamantina Institute and QIMR Berghofer Medical Research Institute. Dr Betz-Stablein is biostatistician with a strength for working with interdisciplinary groups. Currently her research involves the application of statistical and machine learning methods to dermatology images with the goal of improving the early detection of skin cancer. She has received competitive grant funding, has multiple international collaborations and an accelerating publication record. Additionally, Dr Betz-Stablein is recognized as an AStat Accredited Statistician with the Statistical Society of Australia.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 8 July Dr Abate Bashaw and Joachim Torrano

"HPV16 E7-induced epithelial hyperplasia impairs cell-mediated immune responses through regulatory T cells" presented by Dr Abate Bashaw 

"The role of SETDB1/2-mediated H3K9me3 in drug-tolerant cancer" presented by Joachim Torrano

Dr Bashaw recently completed his PhD at the University of Queensland Diamantina Insitute. Currently, he is working as a postdoctoral research fellow in the School of Biomedical Science at the University of Queensland. 

Joachim Torrano is a trained molecular biologist, with expertise in chromatin immunoprecipitation and a background in melanoma research. Joachim completed a BBiomedSc majoring in the Molecular Basis of Health and Disease at the University of Otago in 2015. He was immediately successful in attaining a UQ summer scholarship, taking up a position in Associate Professor Helmut Schaider's lab at the University of Queensland's Diamantina Institute. In 2020 he completed an MPhil (Research) with UQDI and currently continues his work as a Research Assistant helping with various groups at the UQDI's Dermatology Research Centre. 

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 1 July Erin McMeniman and Christine Lee

Structural and functional characterisation of the thrombopoietin receptor and its negative regulator, LNK in myeloid malignancies presented by Christine Lee

Interplay of genetics and environment in Melanoma presented by Erin McMeniman

Dr McMeniman is a Dermatologist with an interest in clinical research, public health and teaching. She has a Master of Public Health with a dissertation project in skin diseases in indigenous children. She completed GP training and subsequently the Dermatology specialty training program.  Dr McMeniman has submitted her final PhD thesis after examiner corrections in February 2020, she studied the phenotypic and genotypic correlations in a cohort of patients with multiple primary melanoma in order to better understand what places patients at risk and to inform targeted screening to improve early detection of melanoma. 

Dr Christine was a PhD student in the Cytokine Receptor Signalling Group at the University of Queensland Diamantina Institute. Christine completed her BSc (Hons) Molecular Biology and Genetics in 2012 (England) and her Masters by Research in 2014 at the Northern Institute for Cancer Research (NICR), Newcastle University (England). Her research was focussing on understanding the basis of accumulation of mutation that drive acute myeloid leukaemia progression, particularly the mutator phenotype. Christine’s current research focus is on the molecular mechanism of JAK-STAT pathway regulation by the thrombopoietin receptor (TPOR) and its negative regulator, LNK. 

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 24 June Dr Janin Chandra and Chanhao Zhou Immune modulation and immunotherapy in HPC-induced malignancies 

Professor Dr. Janin Chandra joined Prof. Ian Frazer’s lab at UQDI in 2012 for postdoctoral research training. She then took on a role as Senior Scientist in the immunotherapy-developing company Admedus Vaccines Pty Ltd located at TRI, where she contributed to the translation of a therapeutic DNA vaccine for genital herpes and HPV+ cancers. Janin returned to UQDI in 2019 as research fellow, where she continues to study immunemodulation induced by HPV and identification of immunotherapy targets.

Chenhao Zhou joined the Frazer Lab – Epithelial Cancer Group in 2017 as a PhD student. His research project focuses on understanding the nature of the adaptive immune response to HPV, by studying a transgenic mouse model expressing HPV16 E7 oncoprotein on the surface of epithelial cells. In particular, he uses single-cell RNA sequencing technology to unravel the heterogeneity of CD4+ T helper and regulatory T cell responses. 

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 17 June  Dr Shannon Joseph and Priscila Oliveira de Lima Endocytosis inhibition in humans to improve responses to ADCC-Mediating antibodies

Shannon completed her undergraduate degree at the University of Queensland with her PhD completed in the laboratory of Prof Jennifer Stow at the IMB (UQ) focussing on the regulation of the intracellular trafficking of the cellular adhesion molecule E-cadherin. She returned to Ass Prof. Fiona Simpson’s laboratory as a Post-doc in 2011 where her work has focussed on the analysing the trafficking of the Epidermal Growth Factor Receptor (EGFR) family and monoclonal antibody therapy responses. Dr Joseph was awarded the PARF Innovation Award (2018-2020) to co-lead the laboratories work in improving monoclonal antibody therapies for breast cancer.

Priscila is currently undertaking her Ph.D. in A/Prof. Fiona Simpson’s lab at UQDI based at TRI. She has completed an investigator initiated contract with Merck KgaA testing the lab’s combination therapy in pre-clinical models of colorectal and renal carcinomas. Priscila has also established at TRI, in collaboration with Prof. Glen Boyle and Prof. Ben Panizza, the world's first preclinical mouse model of cutaneous SCC of the head and neck with perineural invasion. The aim of her current project is to humanise the NSG mouse model to allow preclinical testing of monoclonal antibody therapies for perineural invasion.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 10 June  Associate Professor Melissa Davis, WEHI Computational cancer biology and heterogeneity in breast cancer: Moleculat phenotypes and phenotypic plasticity

Associate Professor Melissa Davis is a computational biologist, with a background in genetics and computational cell biology and expertise in the analysis of genome-scale regulatory networks and knowledge-based modelling.

In 2014 she was awarded a four year National Breast Cancer Foundation Career Development Fellowship, taking up a position as Senior Research Fellow in Cancer Systems Biology at the University of Melbourne. In 2016 Melissa relocated her group to the Bioinformatics Division of the Walter and Eliza Hall Institute for Medical Research, and in 2019 she was appointed as Associate Professor, and Joint Head of the Bioinformatics Division.          

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 3 June Professor Dave Evans and Dr Daniel Hwang

Journeys in Genetic Epidemiology presented by Prof Dave Evans 

A new method to impute parental genotypes using genetic information from their offspring presented by Dr Daniel Hwang

David Evans is Professor of Statistical Genetics at the University of Queensland Diamantina Institute. He completed his PhD in Statistical Genetics at the University of Queensland in 2003, before undertaking a four year post-doctoral fellowship at the Wellcome Trust Centre for Human Genetics, University of Oxford. In 2013 he returned to take up his current position at the University of Queensland whilst continuing to lead an MRC Programme in genetic epidemiology at the University of Bristol. His research interests include the genetic mapping of complex traits and diseases and the development of statistical methodologies in genetic epidemiology including approaches for gene mapping, individual risk prediction, causal modelling and dissecting the genetic architecture of complex traits.

In 2018 Daniel Hwang completed a PhD at the University of Queensland and joined the University of Queensland Diamantina Institute as a postdoctoral research fellow. His research has contributed to fundamental scientific advances in understanding how genes influence taste perception, dietary behaviour and related health risks, which have  since been published in top-tier journals, including the American Journal of Clinical Nutrition and the International Journal of Epidemiology. Daniel’s current research focuses on the development and application of statistical genetics methodologies to assess health impacts of diet and nutrition. Recently, he is involved in a global initiative to study the relationship between the loss of smell and taste and COVID-19.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 27 May  Professor Matt Sweet, IMB A wander through the wonders of innate immunity: in search of mechanisms controlling inflammation and host defence Prof Matt Sweet completed his PhD under the supervision of David Hume in 1996 at The University of Queensland, Australia. He then undertook an NHMRC CJ Martin post-doctoral training fellowship at the University of Glasgow (Scotland, UK) in the laboratory of Eddy Liew. After returning to Australia, he had a number of key roles within the Cooperative Research Centre for Chronic Inflammatory Diseases at The University of Queensland and was appointed to the position of Group Leader at the Institute for Molecular Bioscience (IMB) in 2007. His laboratory at the IMB focuses on the roles of pattern recognition receptors, their signalling components and their downstream target genes in regulating both infectious and inflammatory disease processes.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Wednesday 20 May Dr Aideen McInerney-Leo Dr Tatiane Yanes

Mainstream Genetic Testing and Tatiane will present Clinical implementation of polygenic testing.

Dr McInerney-Leo is a clinician-academic whose interactions with patients have shaped her research questions and fuelled her enthusiasm for the importance of clinical research. Trained as a genetic counsellor, research now focuses on the integration of genomics into clinical care. Her research program has had three primary themes: evaluating the psychosocial impact of genetic conditions and/or genetic testing; evaluating genetics education preferences for patients and healthcare providers; and using next-generation sequencing to increase diagnostic yield for rare disorders.

9:30am-10:30am

Zoom meeting only. Contact [email protected] for seminar link 

Cancelled
18 March

Professor Matt Sweet, IMB A wander through the wonders of innate immunity: in search of mechanisms controlling inflammation and host defence

  Prof Matt Sweet completed his PhD under the supervision of David Hume in 1996 at The University of Queensland, Australia. He then undertook an NHMRC CJ Martin post-doctoral training fellowship at the University of Glasgow (Scotland, UK) in the laboratory of Eddy Liew. After returning to Australia, he had a number of key roles within the Cooperative Research Centre for Chronic Inflammatory Diseases at The University of Queensland and was appointed to the position of Group Leader at the Institute for Molecular Bioscience (IMB) in 2007. His laboratory at the IMB focuses on the roles of pattern recognition receptors, their signalling components and their downstream target genes in regulating both infectious and inflammatory disease processes.

9:30am - 10:30am

Auditorium 

11th March Dr Loredana Spoerri and Phd Student Robert Ju Melanoma phenotypic heterogeneity is regulated by MITF-mediated cell matrix interaction presented by Dr Loredana Spoerri and Uncovering Microtubule-driven Mechanisms of Melanoma Invasion presented by Robert Ju. 

Loredana currently works with Professor Haass to understand the fundamental mechanisms governing melanoma dynamic heterogeneity whereby she applies spatio-temporal confocal imaging in in vitro 3D melanoma models. Her work aims to identify novel avenues to predict and improve melanoma therapy outcomes.

Robert is a joint PhD student in the Stehbens (IMB) and Haass Lab (UQDI) attempting to understand cytoskeletal driven mechanisms of melanoma invasion using novel tools and imaging approaches.

9:30am - 10:30am

Seminar room 2003 

4th March Professor Di Yu Coordinating the fight against pathogens: fundamental immunology and potential translation

Dr. Di Yu was awarded his PhD from the Australian National University (ANU) in 2007. After working in the Garvan Institute of Medical Research, Monash University and ANU, he was recruited to the University of Queensland Diamantina Institute in late 2019 and appointed as a Professorial Research Fellow.

He has frequently been published in top-tier journals including Nature, Nature Immunology, Nature Medicine and Immunity. He is a Highly Cited Researcher (2019).

9:30am - 10:30am

Seminar room 2003 

26th February  Katherine Robbins (Medical Student) Contribution of the Notch4-Wnt5a axis to melanoma plasticity and drug resistance

Katie is investigating the crosstalk and regulation between Notch4 and Wnt5a in melanoma phenotype switching in metastasis.

This work has a strong translational component to elucidate the interplay of two important evolutionary conserved pathways for melanoma progression, metastases and drug resistance.

9:30am-10:30am

Seminar Room 2004 

19th February  PhD Students Carrie Coggon and Amy Pham 

Antibody that exacerbates disease in sepsis and lung infection

Carrie Coggon - A novel method of serum resistance in Escherichia coli mediated sepsis

Amy Pham - Outfoxing Pseudomonas and Burkholderia in chronic lung infections

Carrie is a final year PhD student in the T-Wells group. Her research focuses on determining the mechanisms underlying antibodies that inhibit complement-mediated killing of E. coli.  

Amy is a second year PhD student in the T-Wells group. Her research focuses on the bacterial-host interactions in patients with chronic lung disease pre and post lung transplant. Her work has already led directly to treatment of two patients.

9:30am-10:30am

Seminar Room 2003 

12th February  Professor Nick Hayward The genomic landscape of acral  melanoma

Professor Nick Hayward has studied the molecular genetics of melanoma for over 30 years. He was the first to carry out a linkage scan for melanoma susceptibility genes, to confirm the location of one such gene (CDKN2A), and to report mutations of CDKN2A in Australian families. He played key roles in the identification of CDK4, POT1, ACD, TERF2IP and MITF as melanoma susceptibility genes and in linkage and association scans for melanoma, pigmentation and nevi.

9:30am-10:30am

Seminar Room 2003